MAPT and Alzheimer disease: However, the rationale of using these biomarkers is often similar to the use of the Tau proteins and amyloid-β 1–42, with levels of nearly all the miscellaneous biomarkers, particularly sulfatide [11], being reported to be significantly altered in AD patients; hence, future research is highly warranted to examine their use further.